Overexpression of TREM2 enhances glioma cell proliferation and invasion: a therapeutic target in human glioma
Metrics: PDF 2178 views | HTML 1709 views | ?
Xiao-Qiang Wang1, Bang-Bao Tao1, Bin Li1, Xu-Hui Wang1, Wen-Chuan Zhang1, Liang Wan1, Xu-Ming Hua1 and Shi-Ting Li1
1 Department of Neurosurgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Bin Li, email:
Shi-Ting Li, email:
Keywords: TREM2, glioma, proliferation, invasion, chemokine pathway
Received: May 08, 2015 Accepted: October 08, 2015 Published: October 24, 2015
Gliomas are the most common and aggressive type of primary adult brain tumors. Although TREM2 mutation is reported to be related to Nasu-Hakola disease and Alzheimer’s disease, little is known about the association between TREM2 and gliomas. Here, we reported that TREM2 was significantly overexpressed in glioma tissues compared with non-tumorous brain tissues. Furthermore, TREM2 expression was closely related to pathological grade and overall survival of patients with gliomas. Down-regulation of TREM2 in two glioma cell lines, U87 and U373, resulted in a significant reduction in cell proliferation, migration and invasion and a dramatic increase in S phase arrest and apoptosis. In vivo tumorigenesis experiment also revealed that depletion of TREM2 expression inhibited U87 cell proliferation. Moreover, based on gene set enrichment analysis (GSEA) with The Cancer Genome Atlas (TCGA) dataset, we found that TREM2 was positive related to Kyoto Encyclopedia of Genes and Genomes (KEGG) apoptosis, Cromer metastasis and KEGG chemokine pathways, which was further validated by western blot in TREM2 knockdown glioma cells and indicated a possible mechanism underlying its effects on glioma. In summary, our study suggests that TREM2 may work as an oncogene and a new effective therapeutic target for glioma treatment.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.